Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC)

被引：0
|
作者：
Santini, V. [1 ]
Silverman, L. [2 ]
Seymour, J. [3 ]
Fenaux, P. [4 ]
Mufti, G. [5 ]
Hellstrom-Lindberg, E. [6 ]
Sanz, G.
Finelli, C.
Backstom, J.
McKenzie, D.
Beach, C.
机构：
[1] Aou Careggi Univ Florence, UF Ematol, Florence, Italy
[2] Mt Sinai Sch Med, New York, NY USA
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Univ Paris 13, Hop Avicenne, F-93430 Villetaneuse, France
[5] Kings Coll London, London, England
[6] Karolinska Univ Hosp, Stockholm, Sweden
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70208-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S133 / S133
页数：1
相关论文
共 50 条
  • [41] Prognostic Importance of Duration of MDS Prior to Randomization Between Decitabine (DAC) Vs. Best Supportive Care (BSC) In Elderly IPSS Intermediate-2 and High Risk MDS Patients: Results of the 06011 EORTC-GMDSSG Phase III Trial
    Lubbert, Michael
    Suciu, Stefan
    Platzbecker, Uwe
    Giagounidis, Aristoteles A. N.
    Selleslag, Dominik
    Labar, Boris
    Germing, Ulrich
    Kuendgen, Andrea
    Salih, Helmut R.
    Muus, Petra
    Rueter, Bjoern
    Ganser, Arnold
    Aul, Carlo
    de Witte, Theo
    Wijermans, Pierre W.
    BLOOD, 2010, 116 (21) : 1640 - 1640
  • [42] Estimated net benefit of avelumab (AVE) plus best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis.
    Powles, Thomas
    Cislo, Paul
    Kirker, Melissa
    Chang, Jane
    Gharibian, Norbek
    Thompson, Allison
    Costa, Nuno
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
    Wakelee, H.
    Reck, M.
    Felip, E.
    Altorki, N. K.
    Vallieres, E.
    Liersch, R.
    Oizumi, S.
    Tanaka, H.
    Hamm, J. T.
    McCune, S.
    Bennett, E.
    Gitlitz, B. J.
    McNally, V. A.
    Novello, S.
    Ballinger, M.
    Zou, W.
    Nabet, B.
    Srivastava, M.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S779 - S780
  • [44] A prospective, randomized, double-blinded, placebo controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study.
    Kang, Yoon-Koo
    Boku, Narikazu
    Kang, Won Ki
    Yoon, Harry H.
    Cascinu, Stefano
    Al-Batran, Salah-Eddin
    Houston, Scott
    Park, Cheol Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study
    Lenz, Heinz-Josef
    Tabernero, Josep
    Yoshino, Takayuki
    Lonardi, Sara
    Falcone, Alfredo
    Miron, Maria Luisa Limon
    Saunders, Mark P.
    Sobrero, Alberto F.
    Park, Young Suk
    Monteagudo, Reyes Ferreiro
    Hong, Yong Sang
    Tomasek, Jiri
    Taniguchi, Hiroya
    Ciardiello, Fortunato
    Sassi, Mouna
    Peil, Barbara
    Hastedt, Claudia
    Studeny, Matus
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [46] Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies
    Hofheinz, R.
    Grothey, A.
    Sobrero, A. F.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Lenz, H. -J
    Yoshino, T.
    Cihon, F.
    Strauss, U. P.
    Van Cutsem, E.
    ONKOLOGIE, 2012, 35 : 255 - 255
  • [47] A pharmacoeconomic model of the cost-effectiveness of gefitinib ("Iressa") compared with best supportive care (BSC) in third-line treatment of patients with refractory advanced non-small-cell lung cancer (NSCLC) in the UK
    Ratcliffe, AE
    Beard, SM
    Wolowacz, S
    VALUE IN HEALTH, 2004, 7 (06) : 675 - 676
  • [48] Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.
    Grothey, Axel
    Sobrero, Alberto F.
    Siena, Salvatore
    Falcone, Alfredo
    Ychou, Marc
    Lenz, Heinz-Josef
    Yoshino, Takayuki
    Cihon, Frank
    Wagner, Andrea
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [49] COST-EFFECTIVENESS OF TREATING METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS WHOSE DISEASE FAILED ON ONE PRIOR VEGF-TKI THERAPY WITH EVEROLIMUS COMPARED TO TREATING WITH BEST SUPPORTIVE CARE (BSC) ALONE IN CANADA
    Casciano, R.
    Chulikavit, M.
    El Ouagari, K.
    Wang, X.
    VALUE IN HEALTH, 2011, 14 (07) : A445 - A446
  • [50] COST-EFFECTIVENESS OF TREATING METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS WHOSE DISEASE FAILED ON VEGF-TKI THERAPIES WITH EVEROLIMUS COMPARED TO TREATING WITH BEST SUPPORTIVE CARE (BSC) ALONE: A CANADIAN SOCIETAL PERSPECTIVE
    El Ouagari, K.
    Chulikavit, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 291 - 291
12345